151 related articles for article (PubMed ID: 15271954)
1. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.
Baraldo K; Mori E; Bartoloni A; Petracca R; Giannozzi A; Norelli F; Rappuoli R; Grandi G; Del Giudice G
Infect Immun; 2004 Aug; 72(8):4884-7. PubMed ID: 15271954
[TBL] [Abstract][Full Text] [Related]
2. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
Baraldo K; Mori E; Bartoloni A; Norelli F; Grandi G; Rappuoli R; Finco O; Del Giudice G
Infect Immun; 2005 Sep; 73(9):5835-41. PubMed ID: 16113302
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
Riddell A; Buttery JP; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
Vaccine; 2007 May; 25(19):3906-12. PubMed ID: 17368663
[TBL] [Abstract][Full Text] [Related]
4. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
Badahdah AM; Rashid H; Khatami A
Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
6. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
[TBL] [Abstract][Full Text] [Related]
9. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
10. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
[TBL] [Abstract][Full Text] [Related]
11. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
12. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
13. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
[TBL] [Abstract][Full Text] [Related]
15. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
16. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
[TBL] [Abstract][Full Text] [Related]
17. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
20. Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C.
Dalal J; Rana R; Harale K; Hanif S; Kumar N; Singh D; Chhikara MK
Vaccine; 2019 Aug; 37(36):5297-5306. PubMed ID: 31371227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
